Search results
Results from the WOW.Com Content Network
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), [citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors ().
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
The natural somatostatin receptor ligand, the 14 amino acid peptide somatostatin (A), was abridged to the biologically more stable 8 amino acid peptide Octreotide (OC, B). Introduction of a tyrosine into the 3rd position of the Octreotide sequence resulted in Tyr3-Octreotide (TOC, C), which allows for iodination of the tyrosine residue with the ...
Medical therapy is a second line treatment, and thyrotropinomas respond to treatment with somatostatin receptor ligands such as octreotide or lanreotide. [68] In people with thyrotropinomas, treatment with somatostatin receptor ligands normalized thyroid hormone levels in 80-90% of people, and 42% of people had a decreased tumor size. [68]
Octreotate or octreotide acid is a somatostatin analogue that is closely related to octreotide. Its amino acid sequence is H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH while octreotide has the terminal threonine reduced to the corresponding amino alcohol.
68 Ga DOTA-TATE (gallium-68 dotatate, GaTate) is used to measure tumor SSR density and whole-body bio-distribution via PET imaging. [11] [12] 68 Ga DOTA-TATE imagery has a much higher sensitivity and resolution compared to 111 In octreotide gamma camera or SPECT scans, due to intrinsic modality differences. [11]
Participants were randomly assigned to receive either 177 Lu dotatate with long-acting octreotide or long-acting octreotide, at a higher dose, alone. [15] 177 Lu dotatate was injected through the vein and long-acting octreotide was injected in the muscle. [15] Both, participants and health care providers knew which treatment was given. [15]
It is a long-acting analogue of somatostatin, like octreotide. Lanreotide (as lanreotide acetate) is manufactured by Ipsen. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007. [2]